RU2017145630A3 - - Google Patents

Download PDF

Info

Publication number
RU2017145630A3
RU2017145630A3 RU2017145630A RU2017145630A RU2017145630A3 RU 2017145630 A3 RU2017145630 A3 RU 2017145630A3 RU 2017145630 A RU2017145630 A RU 2017145630A RU 2017145630 A RU2017145630 A RU 2017145630A RU 2017145630 A3 RU2017145630 A3 RU 2017145630A3
Authority
RU
Russia
Application number
RU2017145630A
Other versions
RU2017145630A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017145630A publication Critical patent/RU2017145630A/ru
Publication of RU2017145630A3 publication Critical patent/RU2017145630A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2017145630A 2015-06-23 2016-06-23 Композиции и способы для применения ламеллярных телец в терапевтических целях RU2017145630A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1511058.8A GB201511058D0 (en) 2015-06-23 2015-06-23 Compositions and methods for using lamellar bodies for therapeutic purposes
GB1511058.8 2015-06-23
PCT/GB2016/051890 WO2016207645A1 (en) 2015-06-23 2016-06-23 Compositions and methods for using lamellar bodies for therapeutic purposes

Publications (2)

Publication Number Publication Date
RU2017145630A RU2017145630A (ru) 2019-07-23
RU2017145630A3 true RU2017145630A3 (ru) 2019-07-24

Family

ID=53784408

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017145630A RU2017145630A (ru) 2015-06-23 2016-06-23 Композиции и способы для применения ламеллярных телец в терапевтических целях

Country Status (24)

Country Link
US (1) US20180169145A1 (ru)
EP (2) EP3313377B1 (ru)
JP (1) JP2018518538A (ru)
KR (1) KR20180036958A (ru)
CN (1) CN107920994A (ru)
AU (1) AU2016281764A1 (ru)
BR (1) BR112017027899A2 (ru)
CA (1) CA2990743A1 (ru)
DK (1) DK3313377T3 (ru)
ES (1) ES2754436T3 (ru)
GB (1) GB201511058D0 (ru)
HK (1) HK1248136A1 (ru)
HR (1) HRP20192091T1 (ru)
HU (1) HUE046510T2 (ru)
IL (1) IL256498A (ru)
LT (1) LT3313377T (ru)
MX (1) MX2018000040A (ru)
PH (1) PH12017502432A1 (ru)
PL (1) PL3313377T3 (ru)
PT (1) PT3313377T (ru)
RS (1) RS59551B1 (ru)
RU (1) RU2017145630A (ru)
WO (1) WO2016207645A1 (ru)
ZA (1) ZA201800372B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781123A1 (en) * 2018-04-17 2021-02-24 Lamellar Biomedical Limited Antifibrotic composition
CN114910325A (zh) * 2022-05-17 2022-08-16 浙江峻山生物科技有限公司 一种人工模拟痰液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
US5403592A (en) * 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
AU2943389A (en) * 1988-01-13 1989-08-11 Upjohn Company, The Enhanced production of cellular proteins using butyrate
WO1991012026A1 (en) * 1990-02-14 1991-08-22 Macnaught Pty Limited Means of reducing surgical adhesions
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5462752A (en) * 1994-07-28 1995-10-31 Prp, Inc. Inhibition of platelet binding
WO1998053800A1 (en) * 1997-05-29 1998-12-03 Applied Biotechnologies, Inc. Compositions and methods for preventing adhesion
GB9807298D0 (en) * 1998-04-03 1998-06-03 Britannia Pharmaceuticals Ltd Medicament
CA2319928A1 (en) * 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
US8541472B2 (en) * 2001-12-05 2013-09-24 Aseptica, Inc. Antiseptic compositions, methods and systems
US7498292B2 (en) * 2002-08-15 2009-03-03 The Research Foundation Of State University Of New York Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
GB0322448D0 (en) * 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
CN1634358A (zh) * 2004-11-04 2005-07-06 杨雪 含抗微生物、抗病毒天然精油和磷脂类组合物
WO2008066631A2 (en) * 2006-10-27 2008-06-05 Athena Biotechnologies, Inc. Methods of disrupting quorum sensing to affect microbial population cell density
US20100210017A1 (en) * 2007-01-12 2010-08-19 Gill Ryan T Compositions and methods for enhancing tolerance for the production of organic chemicals produced by microorganisms
WO2014017233A1 (ja) * 2012-07-27 2014-01-30 住友重機械工業株式会社 微生物用活性調節剤及び微生物の活性を調節する方法

Also Published As

Publication number Publication date
IL256498A (en) 2018-02-28
CA2990743A1 (en) 2016-12-29
AU2016281764A1 (en) 2018-01-25
HK1248136A1 (zh) 2018-10-12
RU2017145630A (ru) 2019-07-23
ZA201800372B (en) 2020-05-27
HRP20192091T1 (hr) 2020-02-21
PT3313377T (pt) 2019-10-31
EP3626232A1 (en) 2020-03-25
EP3313377B1 (en) 2019-08-21
WO2016207645A1 (en) 2016-12-29
MX2018000040A (es) 2019-01-10
PH12017502432A1 (en) 2018-07-02
RS59551B1 (sr) 2019-12-31
PL3313377T3 (pl) 2020-01-31
JP2018518538A (ja) 2018-07-12
GB201511058D0 (en) 2015-08-05
US20180169145A1 (en) 2018-06-21
DK3313377T3 (da) 2019-11-11
KR20180036958A (ko) 2018-04-10
ES2754436T3 (es) 2020-04-17
EP3313377A1 (en) 2018-05-02
HUE046510T2 (hu) 2020-03-30
BR112017027899A2 (pt) 2018-08-28
LT3313377T (lt) 2019-11-25
CN107920994A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
BR112017026476A2 (ru)
BR112017026950A2 (ru)
BR112018005153A2 (ru)
RU2017145630A3 (ru)
BE2015C044I2 (ru)
BR0002435B1 (ru)
BR0007834B1 (ru)
BR0003751B1 (ru)
BR0010150B1 (ru)
BR0003746B1 (ru)
BR0003686B1 (ru)
BR0003401B1 (ru)
CN303067994S (ru)
CN303066192S (ru)
BR0003208B1 (ru)
BR0003189B1 (ru)
BR0003166B1 (ru)
BR0002874B1 (ru)
BR0002802B1 (ru)
BR0002694B1 (ru)
BR9813871B1 (ru)
BR0008719B1 (ru)
BR0009942B1 (ru)
BR0109636B1 (ru)
BR0008158B1 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210601